Khan Khurum, Wale Anita, Brown Gina, Chau Ian
Khurum Khan, Ian Chau, Gastrointestinal Unit, the Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, United Kingdom.
World J Gastroenterol. 2014 Sep 21;20(35):12391-406. doi: 10.3748/wjg.v20.i35.12391.
Colorectal cancer (CRC) is one of the commonest cancers with 1.2 million new cases diagnosed each year in the world. It remains the fourth most common cause of cancer-related mortality in the world and accounts for > 600000 cancer-related deaths each year. There have been significant advances in treatment of metastatic CRC in last decade or so, due to availability of new active targeted agents and more aggressive approach towards the management of CRC, particularly with liver-only-metastases; however, these drugs work best when combined with conventional chemotherapy agents. Despite these advances, there is a lack of biomarkers to inform us about the accurate management of the patients with metastatic CRC. It is therefore imperative to carefully select the patients with comprehensive multi-disciplinary team input in order to optimise the management of these patients. In this review we will discuss various treatment options available in management of colorectal liver metastases with potential guidance on how and when to choose these options along with consideration on future directions in management of this disease.
结直肠癌（CRC）是最常见的癌症之一，全球每年有120万新发病例。它仍是全球第四大癌症相关死亡原因，每年导致超过60万例癌症相关死亡。在过去十年左右的时间里，转移性结直肠癌的治疗取得了重大进展，这得益于新型活性靶向药物的出现以及对结直肠癌管理采取的更积极方法，尤其是对于仅肝转移的情况；然而，这些药物与传统化疗药物联合使用时效果最佳。尽管取得了这些进展，但缺乏能够指导我们准确管理转移性结直肠癌患者的生物标志物。因此，必须在多学科团队的全面参与下仔细挑选患者，以优化对这些患者的管理。在本综述中，我们将讨论结直肠肝转移管理中可用的各种治疗选择，并就如何以及何时选择这些选择提供潜在指导，同时考虑该疾病管理的未来方向。
